Exhibit 299

The Adverse Effects of COVID-19 Vaccines in Women of Reproductive Age

Powerpoint Presentation 10/21/22

James A. Thorp, MD

Dr. Thorp Video and Postpartum RN Whistleblower:

https://rumble.com/v20igm6-december-13-2022.html

The Adverse Effects of COVID-19 Vaccines in Women of Reproductive Age

James A Thorp, MD

October 21, 2022 COVID-19 Summit

Brownwood Hotel, The Villages, Florida




Movie Documentary "Died Suddenly" November 2022

Nick Stumphauzer
Matthew Skow


Died Suddenly

Epoch Times, 10.21.2022, Matthew McGreggor, Slide & Analytics by JA Thorp MD




James A Thorp, MD. Data Compiled by Whistleblower Michelle Gershon from Fresno, CA (CCMC & CRMC 8000 births/year)

Slide & Analytics by JA Thorp MD, Data per Daniel Nagasse MD & Mel Bruchet MD, Canada



James A Thorp, MD. Data Compiled by Whistleblowers Daniel Nagasse MD and Mel Bruchet MD

Slide & Analytics by JA Thorp MD, Data per Daniel Nagasse MD & Mel Bruchet MD, Canada



James A Thorp, MD. Data Compiled by Whistleblowers Daniel Nagasse MD and Mel Bruchet MD

Conflicts of Interest - None for US **But What About...**

- The stakeholders in the medical industrial complex aka the "CARTEL"?
- Editor in Chief of NEJM, Eric Rubin?
- Shimabukuro et al in NEJM pushing the C19 vax in pregnancy?
- Mehra et al in LANCET publishing completely falsified data demonizing hydroxychloroquine (HCQ)? — globally responsible for killing millions
- The 21 "advisors" aka charlatans voting to for the FDA to push the C19 shot in children?
- The CDC-FDA receive 46% of annual operating budget from vaccine profits from the pharmaceutical industry and from vaccine patent royalties?

COVID-19 Vaccines and the Impact on Pregnancy **Outcomes and Menstrual Function**

James A Thorp MD ObGyn & Maternal Fetal Medicine, Gulf Breeze, FL

Claire Price, MSPAS, PA-C, Rome, GA

Michael P Deskevich, PhD Modeling and Simulation, Boulder, CO

Stewart Tankersley MD, Montgomery, AL

Albert Benavides BS, San Jose, CA

Megan D Redshaw JD, Palmyra, MO

Peter A. McCullough MD, MPH, Dallas, TX

COVID-19 Vaccines and the Impact on Pregnancy Outcomes and Menstrual Function

age, focusing on pregnancy and menstruation, using data collected by the US Centers for Disease Control and Prevention (CDC) Vaccine Adverse Events Reporting System (VAERS) database. Objectives Assess rates of adverse events (AE) after COVID-19 vaccines experienced by women of reproductive

Design Population based retrospective cohort study

Setting US and global entries in US Centers for Disease Control and Prevention (CDC) Vaccine Adverse Events Reporting System (VAERS)

Participants CDC VAERS entries from January 1, 1998 to June 30, 2022

Setting US and global entries in US Centers for Disease Control and Prevention (CDC) Vaccine Adverse Events Reporting System (VAERS)

Interventions None

system comparing adverse events (AE) reported post COVID-19 vaccines with that of post-Influenza vaccines Main Outcome Measures A proportional reporting ratio (PRR) analysis is performed using data in the VAERS

COVID-19 Vaccines and the Impact on Pregnancy Outcomes and Menstrual Function

all COVID-19 vaccine AE far exceed the safety signal on all recognized thresholds smaller than 0.05). When normalized by time-available, doses-given, or persons-received, with a significant increase in AE with all proportional reporting ratios of > 2.0: placental thrombosis, low amniotic fluid, and fetal death/stillbirth (all p values were much vascular mal-perfusion, fetal growth abnormalities, fetal abnormal surveillance, fetal fetal cystic hygroma, fetal cardiac disorders, fetal arrhythmia, fetal cardiac arrest, fetal menstrual abnormality, miscarriage, fetal chromosomal abnormalities, fetal malformation, Results COVID-19 vaccines, when compared to the Influenza vaccines are associated


prospective trials document safety in pregnancy and long-term follow-up in offspring moratorium on the use of COVID-19 vaccines in pregnancy is advised until randomized following COVID-19 vaccinations than that of Influenza vaccinations. A worldwide Conclusions Pregnancy and menstrual abnormalities are significantly more frequent

Adverse Event	US Count of AE reports post Vaccine	US Rate of reported AE (count/Month)	US Rate of reported AE (count/billion doses)	US Rate of reported AE (count/billion people vaccinated)
Menstrual abnormality	6352 / 54	353 / 0.184	10700 / 16.4	24400 / 173
Miscarriage	1232 / 259	68.4 / 0.881	2070 / 78.5	4740 / 827
Fetal chromosomal abnormalities	7/0	0.389 / 0.00	11.7 / 0.00	26.9 / 0.00
Fetal malformation	2/1	0.111 / 0.00340	3.35 / 0.303	7.69 / 3.19
Fetal cystic hygroma	5/0	0.278 / 0.00	8.39 / 0.00	19.2 / 0.00
Fetal cardiac disorders	10 / 2	0.556 / 0.00680	16.8 / 0.606	38.5 / 6.39
Fetal arrhythmia	3/0	0.167/0.00	5.03 / 0.00	11.5 / 0.00
Fetal cardiac arrest	3/5	0.167 / 0.00	5.03 / 0.00	11.5 / 0.00
Fetal vascular mal-perfusion	5/0	0.278 / 0.00	8.39 / 0.00	19.2 / 0.00
Fetal growth abnormalities	59/20	3.28 / 0.0680	99.0 / 6.06	227 / 63.9
Fetal abnormal surveillance	125 / 36	6.94 / 0.122	210 / 10.9	481 / 115
Fetal placental thrombosis	5/0	0.278 / 0.00	8.39 / 0.00	19.2 / 0.00
Low amniotic fluid	11/1	0.611/0.00340	18.4/0.303	42.3 / 3.19
Fetal stillbirth	168 / 42	9.33 / 0.143	282 / 12.7	646 / 134

Adverse Event Menstrual abnormality Miscarriage	Global Count of AE reports post Vaccine 12843 / 65 3338 / 325	Global Rate of reported AE (count/Month) 714 / 0.221 185 / 1.11	Global Rate of reported AE (count/billion doses) 1060 / 0.985 277 /4.92	Global Rate of reported AE (count/billion people vaccinated) 2460 / 8.43 638 / 42.2
Fetal chromosomal abnormalities	10/0	0.556 / 0.00	0.829 / 0.00	
Fetal malformation	22 / 2	1.22 / 0.00680	1.82 / 0.0303	
Fetal cystic hygroma	8/0	0.444 / 0.00	0.663 / 0.00	
Fetal cardiac disorders	18/2	1.00 / 0.00680	1.49 / 0.0303	
Fetal arrhythmia	5/0	0.278 / 0.00	0.414 / 0.00	
Fetal cardiac arrest	20/0	1.11/0.00	1.66 / 0.00	
Fetal vascular mal-perfusion	12/0	0.667 / 0.00	0.994 / 0.00	
Fetal growth abnormalities	188 / 24	10.4 / 0.0816	15.6 / 0.364	
Fetal abnormal surveillance	178 / 45	9.89 / 0.153	14.7 / 0.682	
Fetal placental thrombosis	6/0	0.333 / 0.00	0.497 / 0.00	
Fetal stillbirth	402 / 64	22.3 / 0.218	33.3 / 0.970	

Fetal stillbirth	Low amniotic fluid	Fetal placental thrombosis	Fetal abnormal surveillance	Fetal growth Abnormalities	Fetal vascular mal-perfusion	Fetal cardiac arrest	Fetal arrhythmia	Fetal cardiac disorders	Fetal cystic hygroma	Fetal malformation	Fetal chromosomal abnormalities	Miscarriage	Menstrual abnormality	Adverse Event
82 [26.5-184] p = 0.0	17 [8.00-25.0] p = 5.1X10 ⁻⁰⁶	p = 0.0096	83 [26.9-193] p = 0.0	126 [42.00-210.0] $p = 0.0$	p = 0.00015	$p = 6.9 \times 10^{-07}$	p = 0.020	17 [8.00-27.0] p = 2.6x10 ⁻⁰⁶	p=0.0024	21 [10.0-32.0] p = 1.9 × 10 ⁻⁰⁷	p= 0.00058	177 [114.4-283.5] p = 0.0	4257 [1589.1-12893] p = 0.0	Relative Rate
135 [48.25-412.0] p = 0.0	11 [5.00-18.0] p = 0.00029	p = 0.020	68 [21.6-140] p = 0.0	43 [14.0-72.0] $p = 0.0$	p = 0.020	p = 0.088	p= 0.088	10 [4.00-17.0] p = 0.00058	p=0.020	2 [0.0-5.0] p = 0.20	p= 0.0048	83 [50.8-143] p = 0.0	2524 [894.57-6419.0] p = 0.0	(by time)
38 [21.1-73.0] p = 0.0	16 [7.00-25.0] p=5.1x10 ⁻⁰⁶	p = 0.0096	25 [12.2-58.7] p = 0.0	$56 [20.7 \cdot 189] p = 0.0$	p = 0.00015	$p = 6.9 \times 10^{-07}$	p = 0.020	16 [6.00-26.0] p = 2.6x10 ⁻⁰⁶	p = 0.0024	20 [7.67-31.0] p = 1.9x10 ⁻⁰⁷	p = 0.00058	57 [44.3-74.7] p=0.0	1192 [673.95-2162.8] p = 0.0	Relative Rate
26 [12.2-60.0] p = 0.0	11 [4.00-18.0] p=0.00029	p = 0.020	24 [10.1-63.0] p = 0.0	22 [7.14-64.0] p = 0.0	p = 0.020	p = 0.088	p = 0.088	9 [3.0-16] p = 0.00058	p = 0.020	2 [0.0-5.0] p = 0.20	p = 0.0048	27 [20.2-36.5] p=0.0	738 [391.6-1584] p = 0.0	(by dose)
5 [3.4-7.2] p = 0.0	14 [4.67-25.0] p= 5.1 x 10 ⁻⁰⁵	p = 0.0096	6 [4.1.9.0] p=0.0	12 [7.42-21.4] p=0.0	p=0.00015	$p = 6.9 \times 10^{407}$	P = 0.020	12 [3.60-25.0] p = 2.7x10 ⁻⁰⁵	p = 0.0024	15 [4.50-30.0] $p = 2.1 \times 10^{-06}$	p = 0.00058	15 [13.3-17.5] p = 0.0	298 [223.0-406.0] p = 0.0	Relative Rate
9 [6.9-13] p = 0.0	9 [2.5-17] p = 0.00029	p = 0.020	4 [2.9-6.6] p=0.0	4 [2.2-6.8] p = 3.2 x 10 ⁻⁰⁷	p=0.020	p = 0.088	P = 0.088	6 [1.5-15] p = 0.0047	p = 0.020	2 [0.0-5.0] $p = 0.20$	p = 0.0048	6 [5.0-6.7] p = 0.0	145 [108.6-197.4] p = 0.0	(by person vaccinated)

magnitude, indicating a large effect across many different AE - all substantially greater than 1. COVID-19 vaccination compared to Influenza vaccinations. Note the log scale spanning multiple orders of vaccines by dose given. A value greater than 1 implies that AE are reported more frequently after Figure 1. Global relative rates of AE reports after COVID-19 vaccines versus those after Influenza



32 Independent Sources Collaborating VAERS C19 Vax Injury

- L <u>UK government</u>
- 2. UK Yellow card
- 3. EMA EudraVigillance
- 4. WHO VigiAccess
- 5. 61,000 dead millennials
- 6. OneAmerica Insurance
- 7. Lincoln insurance
- 8. 33 DEAD Canadian docs
- Athletes dropping dead
- 10. All Cause mortality way up
- 11. Drs Palmer & Bhadki
- 12. Dr. Arne Burkhardt
- 13. Alexandra Latypova
- 14. Richard Hirschman embalmer
- 15. Canadian stillbirths
- Birth rates down 10% globally

- 17. Dr Daniel Nagase, Canada
- 18. Dr. Peter McCullough
- 19. DMED US Military database Dr. Theresa Long
- 20. World Council for Health
- 21. Spiro Pantazatos MD MPH
- 22. 1,366 AE med journal publications in 15 mor
- 23. Costa Rica
- 24. Scandinavian Countries
- 25. Uruguay
- 26. Germany
- 27. Italy
- 28. Romania
- 29. Denmark
- 30. 78 countries in world have dropped mandates
- 31. Steve Kirsch formal questionnaire
- 32. Pfizer 5.3.6 post-marketing analysis

COVID-19 and the Unraveling of Experimental Medicine – Part III

Appendix 1. Subject-wise segregation of 1,366 references

COVID-19 Vaccine Published Complications Subject of Article(s)	Number of Publication(s)	Reference Numbers in the Hyperlink
Anaphylaxis	47	1-47
Antiphospholipid Antibodies	3	48 - 50
Arterial & Venous Thromboembolism	160	51 - 210
Arthritis	2	211 - 212
Auto-Immune Disorders	21	213 - 233
Autopsy Findings	11	234 - 244
Blood Disorders	10	245 - 254
Cancer	7	255 - 261
Cardiac Disease (Myocarditis / Pericarditis)	336	262 - 597
Cardiac Disease (other)	15	598 - 612
Dementia / Alzheimer's / Delirium	2	613 - 614
Encephalopathy & Neurological Injury	46	615 - 660
Eye Diseases	11	661 - 671
Facial Nerve Palsy	28	672 - 699
Gastroparesis	1	700
Guillain Barre Syndrome	51	701 - 751
Hearing Loss / Tinnitus	13	752 - 764
Hemolytic Uremic Syndrome	1	765
Hemorrhage	38	766 - 803

Appendix 1 Continued Below

ary Disorders 23 asthy 60 osis 1 ters 5	/ Bursitis	1.9 7 7 8 60 60 1 1 1 1 1 1 2 7 7 7 7 7 7 7 4 1 4 1 4 1 4 1 4 1 4 1 4 1 4 1 4 1 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8	804 - 8222 803 - 825 823 - 825 825 - 915 916 917 - 921 922 923 - 927 928 - 939 940 - 945 946 - 952 994 - 1026 1027 - 1235 1126 - 1262 1236 - 1310
lers	lers	1 0	917 - 921
H		5	923 - 927
V +		12	928 - 939
Syndrome 5		7	940 - 945
5 5 6	A COLUMN A C	41	953 - 993
Il Syndrome		33	994 - 1026
Il Syndrome		209	1027 - 1235
Il Syndrome		27	1236 - 1262
Il Syndrome		48	1263 - 1310
Recase		56	1311 - 1366
Receive	TOTAL 1	1366	1-1366

*Hyperlink to 1,366 references for COVID-19 vaccine associated complications: https://www.thegms.co/publichealth/pubheal-rw-22042302-references.pdf

Thorp KE, Thorp JA, Thorp EM. COVID-19 and the Unraveling of Experimental Medicine - Part III. G Med Sci. 2022; 3(1):118-158. https://www.doi.org/10.46766/thegms.pubheal.22042302


Implications for Clinicians and Policy Makers


data are available. authors of this study concur with the recommendations previously made by the UK government and the case of the rotavirus vaccine was removed after only a few non-lethal cases of intussusception. The with the COVID-19 vaccines. The swine flu vaccine was removed from market after 26 deaths and in the World Council for Health: COVID-19 vaccines should not be used in pregnancy until long-term safety There is a precedent in medicine for halting vaccines with safety signals far less than what is observed

safe and effective especially when started early in the COVID-19 disease process are at lower risk for mortality and severe outcomes than are non-pregnant patients. There is now even greater risk for infectious complications. Pinelle recent large-scale study indicates that pregnant patients Assumptions at the outset of the COVID-19 pandemic erroneous. Pregnant women DO NOT appear to be more evidence that early treatment of COVID-19 with vitamins, supplements and repurposed drugs are

GERMANY:


- 14.3% year-over-year drop in births
- Connection between the mass vaccine rollout in the populations of childbearing significance -- significant decline in births





From the official German Federal Statistical Office government data:

1 Q 2018-2022 Births Norway. % reduction 2022 1 Q minus 16,1 %



Source: Tim Truth Substack (7/26/22)

NORWAY:

Norway births in Q1 of 2022 **down**16% from Q1 2021




Birth Rate Trends: Is There a Connection to the Vaccines?

SWEDEN:


April 2022 was down
 10.4% from April 2021. Q1
 2022 was down 5.2%








Source: Tim Truth Substack (7/26/22)


Nations Statistical Division -Live Birth Stats from United compiled by FLCCC Analyst Juan Chamie

















Total Births

January February

March

April

May

June

July

August September October November December

200-

400-

Year


2020 2022 2021

2019 2018 2017

2016 2015 2014


2013


600-











C19 Vaccines in Pregnancy and Breastfeeding UK Government Recommends Against

and nongovernmental organizations. Recent documents from the UK government state: Results of this study also align with recommendations from governments

to rule out known or suspected pregnancy prior to vaccination." potential could be supported provided healthcare professionals are advised sufficient reassurance of safe use of the vaccine in pregnant women cannot "In the context of supply under Regulation 174, it is considered that be provided at the present time; however, use in women of childbearing

Pharma, CDC & FDA Killed & Injured Millions of Innocent Victims Reproductive Toxicology a Mandatory Requirement "They Lied to the World" - Alexandra Latypova Epoch Times August 15, 2022

- mRNA & spike protein pass all barriers, dam to fetus
- Dams experienced toxicity during gestation at highest level of antigen detected
- Toxicity admitted: loss of fertility, inability to use hind limb, other effects
- Other toxicities & possible deaths waived off "non-mRNA 1273 related"

<u>dra Latypova</u> GETTR @ Jamesathorpmd

Lethal Skeletal Dysplasias







GETTR @ Jamesathorpmd

JAMA Pediatrics. Published online September 26, mRNA COVID-19 Vaccines in Human Breast Milk 2022

- 5 of 11 had mRNA from the vaccine in the breast milk
- The authors attempt to marginalize these findings, an egregious excuse for pushing the vaccine in pregnant and breast-feeding women
- breast feeding in recently vaccinated mothers I know of at LEAST three perfectly healthy newborns NOW DEAD after

Codominant IgG and IgA Expression with Minimal Vaccine mRNA in Milk of BNT162 Vaccinees

HUBUST 13, ZUZI

GETTR @JamesAthorpMD




Fig. 4 Minimal transfer of BNT162b2 mRNA into human milk. a Standard curve of cDNA reverse-transcribed from vaccine derived BNT162b2-spiked human milk was made and used as a positive control. n ≥ 6 technical replicates; means are shown with error bars indicating the standard error of measurement (SEM). b Heat map of calculated median BNT162b2 mRNA concentrations in vaccinated women (n = 10) at four time points as indicated. Cr cycle threshold, pg³ picogram, ng⁵ nanogram, mL° milliliter, T1 pre-vaccination, T2 1-3 days after dose 1 of BNT162b2 vaccine, T3 7-10 days after dose 1 of BNT162b2 vaccine, T3 3-7 days after dose 2 of BNT162b2 vaccine, SI conversion factors: to convert concentration from pg to kg, multiply values by 10¹2. SI conversion factors: to convert concentration from ng to kg, multiply values by 10¹2. SI conversion factors: to convert concentration from ng to kg, multiply values by 10²2. SI conversion factors: to convert concentration from mg to kg, multiply values by 10²2. SI conversion factors: to convert concentration from mg to kg, multiply values by 10²2. SI conversion factors: to convert concentration from mg to kg, multiply values by 10²2. SI conversion factors: to convert concentration from mg to kg, multiply values by 10²2. SI conversion factors: to convert concentration from mg to kg, multiply values by 10²2. SI conversion factors: to convert concentration from mg to kg, multiply values by 10²2. SI conversion factors: to convert concentration from mg to kg, multiply values by 10²2. SI conversion factors: to convert concentration from mg to kg, multiply values by 10²2. SI conversion factors: to convert concentration from mg to kg, multiply values by 10²2. SI conversion factors: to convert concentration from mg to kg, multiply values by 10²2. SI conversion factors: to convert concentration from mg to kg, multiply values by 10²2. SI conversion factors: to convert concentration from mg to kg, multiply values by 10²2. SI conversion factors: to convert concentration from mg to kg, multiply va

Analysis of Vaccine Reactions After COVID-19 Vaccine Booster Doses Among Pregnant and Lactating Individuals

Survey data (as in V-safe) is dangerous and easily manipulated – often auto-populated

Selected population - over 50% were nurses and mainly white

after vaccination. This is NOT consistent with the "Most pregnant (97.6%) and lactating (96.0%) individuals *reported* no obstetric or lactation concerns

No query into the health of the baby or change in feeding habits in the online survey

Of the 4% of lactating women who had problems, the problems were not listed or quantified


GlaxoSmithKline and AstraZeneca Conflict of Interest Disclosures:Kachikis & Englund affiliations with Pfizer, Merck,

JAMA Netw Open Sep 1, 2022

An Independent Research Study Collecting Data Around Women's Cycle Changes Tiffany Parotto, CEO & Developer of MyCycleStory.com

Tiffany Parotto, CEO President of

MyCycleStory.com. Over more than 100 years,
fewer than 40 cases of decidual cast shedding —
during which the uterus' thick mucous lining is shed,
intact — have been reported. But over a 7.5 month
period in 2021, 292 women experienced it, raising
questions about whether Covid-19 vaccines could
be to blame.



Parotto T, Thorp JA, Hooker B, Mills PJ, Newman J, Murphy L, et al. COVID-19 and the surge in Decidual Cast Shedding. G Med Sci. 2022; 3(1): 107-117.

Menstrual Irregularities and the COVID-19 Pandemic MyCycleStory.com (MCS) Part I: COVID-19 and the Surge in Decidual Cast Shedding (DCS)

Significant reporting of DCS via MCS with 294 in 7.5 months of 2021

Prior 109 years pre-pandemic < 40 reported in the medical literature

Usual associations: ectopic pregnancy, miscarriage, prolonged progesterone


Causes of surge in pandemic????


Parotto I, Thorp JA, Hooker B, et al. Gazette of Medical Sciences. 2022; 3(1):107-117. GETTR @ Jamesathorpmd



Possible Causes of Abnormal Bleeding

- 1. Microvascular clotting at level of endometrium?
- 2. Ovarian inflammation from LNP's disrupting hormones?
- 4. Inflammatory assault from "vaxx" components at endometrium? 3. Autoimmune reaction of at endometrium?
- 5. Spike protein assault from "vaxx"?
- 6. Hypothalamic-pituitary abnormalities / inflammation?
- 7. Other endocrine factors, thyroid, adrenal?








Potential Treatments for Severe Menstrual Abnormalities Associated with the COVID-19 Pandemic

- Non-steroidal anti-inflammatory meds (ibuprofen 600 mg PO Q 6 hours
- Combined oral contraceptive pill (ethinylestradiol 30 ug / levonorgestrel 150 ug)
- Progestogens
- Anti-fibrinolytic transxamic acid 3.9 to 4 g/day for 4-5 days
- Danazol 200 mg po q day
- Analogues of gonadotrophin releasing hormone (SNR-
- treatment of dysfunctional uterine bleeding. Levonorgestrel releasing IUD developed for contraception but is also effective in the
- Surgical treatment includes D&C, endometrial ablation, and hysterectomy.

bin JA et al 2016 Whitak









32 yo G2 P0010 at 36 weeks gestation.

Pfizer vaxxed x 3 18 months prior 17 months prior 11 months prior

She has had 43 Vaccines listed on her chart...



32 yo G2 P0010 at 36 weeks gestation.

Pfizer vaxxed x 3 18 months prior 17 months prior 11 months prior

She has had 43 Vaccines listed on her chart...

MENINGOCOCCAL CONJUGATE (MCV4P) FLU VACCINE QUAD IIV4 SPLIT PF IM **➢ Administration History** Medications VARICELLA TD (ADULT), 5 LF TETANUS TOXOID, ADSORBED, PF PFIZER SARS-COV-2 COVID-19 VACCINE 0.3ML MENINGOCOCAL MENINGITIS Human Papilloma Virus Vaccine FLU VACCINE QUAD IIV4 SPLIT 0.25 ML IM HEP B VACCINE, PED/ADOL HEP A PEDS 2 DOSE Vaccine *Immunizations* 7/21/2008, 9/15/1995 8/23/2022, 10/5/2020, 7/16/2007 5/21/2012 11/17/2017 9/1/1997, 3/1/1994, 1/1/1993, 11/1/1992 11/27/2021, 5/1/2021, 4/10/2021 9/23/1997, 12/13/1993 9/13/2018, 9/13/2017, 9/13/2016, 9/13/2016, 9/11/2015, 10/1/2014, 9/15/2013, 9/15/2012, 9/20/2011 7/11/2013 7/16/2007 2/20/2008, 9/17/2007, 7/16/2007 7/1/1993, 11/1/1992, 10/1/1992 7/27/2010, 7/28/2009 9/1/1997, 3/1/1994, 3/1/1993, 1/1/1993, 11/1/1992 9/13/2019 10/6/2022, 9/13/2021, 9/11/2020 Admin Dates

35 yo G10 P4054 36 weeks/5 days gestation

Pfizer vaxx
22 months ago
18 months ago
10 months ago

